No registrations found.
ID
Source
Brief title
Intervention
Outcome measures
Primary outcome
Gastric emptying.
Secondary outcome
Symptoms.
Background summary
This is a randomized, placebo-controlled, double-blind study with patients who'll undergo abdominal surgery. They will be treated with Ketotofen 4 mg or 12 mg or placebo per day. The patient will start his medication intake 3 days before surgery till 2 days after surgery. Post operative effectivity will be determined by scintigraphy to look at gastric retention and colontransit. This scintigraphy will take place 24 hours after surgery. The patients will be clinical evaluated by filling out a daily symptom score list.
Study objective
N/A
Study design
N/A
Intervention
Ketotofen 4 mg or 12 mg or placebo per day.
P.O. Box 22660
G.E.E. Boeckxstaens
Meibergdreef 9
Amsterdam 1100 DD
The Netherlands
+31 (0)20 5667375
g.e.boeckxstaens@amc.uva.nl
P.O. Box 22660
G.E.E. Boeckxstaens
Meibergdreef 9
Amsterdam 1100 DD
The Netherlands
+31 (0)20 5667375
g.e.boeckxstaens@amc.uva.nl
Inclusion criteria
Laparotomy for (malignant) proces originaty from colon or female reproduction organs.
Exclusion criteria
Pre-operative radiation, intake of medication with effect on the Gastrointestinal motility, intake of immunosuppressiva, intake of anti-allergy medication, intra-abdominal inflammation (cholecystitis or absces included).
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL16 |
| NTR-old | NTR38 |
| Other | : N/A |
| ISRCTN | ISRCTN34927143 |